Optimal treatment in men with intermediate (IM) risk prostate cancer (PCa) is still a matter of debate. MRI has improved pre-treatment risk stratification and PCa volume estimation. However, index lesion (IL) volume, which is associated with oncological outcome, is still not included in patient risk assessment. We hypothesise that men with indolent PCa among patients with IM risk disease can be identified by adding MRI IL volume in a large contemporary cohort of men treated with radical prostatectomy (RP).METHODS: We identified 3088 patients with low and IM PCa receiving RP at 11 referral centres. All patients had a positive MRI (PIRADS!3). The aim was to compare oncological outcomes of low risk ISUP 1 PCa (Group 1) and IM risk ISUP 2-3 PCa, stratified according to the most informative IL volume cut-off at MRI, namely IL diameter <10 mm (Group 2) and !10 mm (Group 3). The outcome of this study was biochemical recurrence (BCR) after RP. Multivariable Cox regression analyses (MVA) were used to compare BCR-free survival in Group 1 vs 2 vs 3 after accounting for the following confounders: PSA, prostate volume, PIRADS score, and percent of positive biopsy cores. We then compared BCR-free survival using the adjusted Kaplan-Meier method (KM).RESULTS: 247 (8%), 1747 (57%), and 1094 (35%) patients harboured ISUP group 1, 2, and 3 at RP, respectively. In all, 247 (8%), 2110 (68%), and 731 (24%) patients were stratified into Group 1, 2, and 3, respectively. Median follow-up was 50 months and 227 patients had BCR. The 5-yr BCR-free survival probability was 84%, 86%, and 73%, among patients in group 1, 2, and 3, respectively (Figure 1; p<0.01). At MVA, with Group 1 as reference, only Group 3 was associated with the rate of BCR (Group 2: HR: 0.94, p[0.9; Group 3: HR: 2.32, p[0.03). Specifically, patients with PCa ISUP 1 and PCa ISUP 2-3 with IL <10 mm did not exhibit any differences in BCR-free survival after RP (p[0.6) (Figure 1).CONCLUSIONS: Patients with low volume ISUP 2-3 with IL size <10 mm appear to have comparable oncological outcomes in terms of BCR-free survival to patients with ISUP 1 disease after RP. These results should be taken into account for patient counselling and in decision making of active treatment vs active surveillance in patients with low volume IM risk PCa.